Tutorials
Fulcrum Therapeutics Inc logo

Fulcrum Therapeutics Inc

$ 7.70 +0.295 (+3.99%) 12:17 PM EST
P/E:
At Loss
P/B:
1.75
Market Cap:
$ 314.12M
Enterprise V:
$ 122.39M
Volume:
116.61K
Avg Vol (2M):
733.90K
Volume:
116.61K
Market Cap $:
314.12M
PE Ratio:
At Loss
Avg Vol (2-Month):
733.90K
Enterprise Value $:
122.39M
PB Ratio:
1.75
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Fulcrum Therapeutics Inc
NAICS : 325412 SIC : 2834
26 Landsdowne Street, Cambridge, MA, USA, 02139
Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.
Name Current Vs Industry Vs History
Cash-To-Debt 12.81
Equity-to-Asset 0.86
Debt-to-Equity 0.08
Debt-to-EBITDA -0.17
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.68
Distress
Grey
Safe
Beneish M-Score -1.9
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 62.28
9-Day RSI 64.08
14-Day RSI 61.9
6-1 Month Momentum % -47.8
12-1 Month Momentum % -28.81

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.94
Quick Ratio 10.94
Cash Ratio 10.67
Days Sales Outstanding 48.41

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -33.9

Financials (Next Earnings Date:2022-08-11)

FULC's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:FULC

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 16.966
EPS (TTM) ($) -2.39
Beta 2.65
Volatility % 347.73
14-Day RSI 61.9
14-Day ATR ($) 0.648469
20-Day SMA ($) 6.1305
12-1 Month Momentum % -28.81
52-Week Range ($) 3.21 - 33.0975
Shares Outstanding (Mil) 40.85

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Fulcrum Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More